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  67 
ABSTRACT 68 
Background: Vasopressin receptor mediated vasoconstriction is thought to be involved in the 69 
pathogenesis of organ failure in acute-on-chronic liver failure (ACLF).  70 
Methods: We studied the association between six single nucleotide polymorphisms (SNPs) of the 71 
vasopressin 1a receptor gene and the development of organ failure in 826 patients admitted for 72 
acute decompensation of liver cirrhosis (AD, n=641) or ACLF (n=185).  73 
Results: No associations were found for SNPs with presence of circulatory or renal failure. A C>T 74 
mutation in SNP rs7308855 and a T>A mutation in SNP rs7298346, showed an association with the 75 
presence of coagulation failure in the whole population (n=61, p=0.024 and p=0.060, respectively) 76 
and in the subgroup of patients with ACLF (n=44, p=0.081 and p=0.056, respectively).  77 
Conclusion: Genetic variation in the vasopressin 1a receptor was found not to be associated with 78 
circulatory or renal failure, but with the presence of coagulation failure in patients with AD and 79 
ACLF. 80 
 81 
Key-words: arginine vasopressin 1a receptor; single nucleotide polymorphisms; cirrhosis; acute-on-82 
chronic liver failure 83 
  84 
INTRODUCTION 85 
Acute decompensation of liver cirrhosis (AD) is defined as the acute development of one or more 86 
complications of the underlying liver disease. Acute-on-chronic liver failure (ACLF) is a distinct 87 
syndrome from AD, as it is associated with the presence of organ failure, high short-term mortality 88 
rates, age and precipitating events [1]. Systemic inflammation seems to play a key role in the 89 
development of ACLF. Also systemic hemodynamic dysfunction and the activation of endogenous 90 
vasoconstrictor systems are thought to be involved in the pathogenesis [2]. A decreased systemic 91 
vascular resistance leads to the activation of compensatory vasoconstrictor systems and the non-92 
osmotic release of arginine vasopressin (AVP) [3, 4]. AVP is a neurohypophyseal hormone, which 93 
plays a prominent role in the cardiovascular system and mediates vascular smooth muscle 94 
contraction via the V1a receptor (AVP1aR) [5]. A previous study has found an association between 95 
single nucleotide polymorphisms (SNPs) in the promotor region of AVP1aR and presence of essential 96 
hypertension in non-obese Japanese subjects [6]. Considering the important role of AVP1aR in 97 
regulating vascular tone and baroreceptor sensitivity [7], we hypothesized that heterogeneity in 98 
AVP1aR may affect the risk of developing renal and circulatory failure in cirrhotic patients. This may 99 
be relevant information in clinical practice, as patients with certain genotypes of AVP1aR may need 100 
more intensive surveillance and treatment. Aim of this study was to investigate whether genetic 101 
variation of AVP1aR is associated with the presence of circulatory failure, renal failure and outcome 102 
in cirrhotic patients with AD and ACLF.  103 
 104 
 105 
 106 
  107 
METHODS 108 
 109 
Patients  110 
This study is an ancillary study of the prospective, observational CANONIC study [1]. In that study, 111 
1343 patients hospitalized for AD of cirrhosis were included between February and September 2011. 112 
The HCB-IDIBAPS Biobank in Barcelona (Spain) manages the CANONIC database and storage of 113 
biomaterials. The study protocol conformed to the ethical guidelines of the 1975 Declaration of 114 
Helsinki (6th revision, 2008). Initially, we performed a pilot study including 188 patients from the 115 
CANONIC database without (n=93) and with ACLF (n=95). These samples were centrally randomly 116 
selected as stratified groups by the HCB-IDIBAPS Biobank personnel, who were not involved in this 117 
study. Based on these preliminary results, the study population was extended involving all 826 118 
CANONIC patients who gave informed consent for isolation and storage of genomic DNA for future 119 
research. ACLF and individual organ failures were defined using the CLIF-Organ Failure score [8]. This 120 
scoring system is a simplification of the CLIF-sequential Organ Failure Assessment (SOFA) scale, 121 
which was developed by the CANONIC study for defining and diagnosing organ failure in cirrhotic 122 
patients. The CLIF-Organ Failure score involves a total of 6 organ systems (i.e. liver, kidney, brain, 123 
coagulation, circulation and respiration). For each system, 3 subscores have been defined: subscore 124 
1= normal or moderate organ dysfunction, subscore 2= marked organ dysfunction, subscore 3= 125 
organ failure. According to the CLIC-Organ Failure score, the following criteria are defined for 126 
individual organ failures: liver failure= bilirubin ≥12 mg/dl; kidney failure= creatinine ≥2 mg/dl and 127 
<3.5 mg/dl (subscore 2) or creatinine ≥3.5 mg/dl or renal replacement (subscore 3); cerebral failure= 128 
West-Haven grade 3-4; coagulation failure= INR ≥2.5; circulatory failure= use of vasopressors; 129 
respiratory failure= PaO2/FiO2 ratio ≤200 or SpO2/FiO2 ratio ≤214. Patient characteristics and 130 
clinical data were retrieved from the CANONIC database.  131 
 132 
 133 
Genotyping 134 
For genetic testing, DNA was isolated from 10 mL EDTA blood of each patient with consent for 135 
genetic testing. DNA samples were stored at -80°C. Genotyping was performed in the Leiden 136 
University Medical Centre, Leiden, the Netherlands. Six SNPs of AVP1aR with potential clinical 137 
relevance were identified from preliminary studies [6, 9]. The genotype of rs7298346 was identified 138 
by polymerase chain reaction (PCR) with allele-specific amplification primers. Genotypes of the other 139 
5 variants were identified by PCR followed by restriction fragment length polymorphism. PCR was 140 
performed in a 25 µl reaction volume containing 50 ng DNA, ReddyMix (Thermo Scientific, Waltham, 141 
MA, USA) and 0.24 µM of each primer. Restriction enzymes (New England BioLabs, Ipswich, MA, 142 
USA) used to determine the genotypes were BfaI, MLuCI, PstI, Tsp45I and Sau3AI for rs113481894, 143 
rs11174817, rs7308855, rs1042615 and rs10747983 respectively. The DNA fragments were 144 
separated by electrophoresis on 2,5% agarose gel, and visualised by staining with ethidium bromide. 145 
The investigators were blinded for clinical outcomes during determination of genotypes of the 146 
AVP1a receptor gene. 147 
 148 
Statistical analysis 149 
For all SNPs, deviation from Hardy-Weinberg equilibrium was calculated using Pearson’s chi 150 
–square test. The association between SNPs and presence of ACLF, individual organ failures and 151 
levels of relevant laboratory values were evaluated using Fisher’s exact test. A Cox proportional 152 
hazard regression analysis was performed in order to assess the relation of SNPs with overall survival 153 
in all patients and in the subgroup of patients with ACLF.  154 
 155 
 156 
157 
RESULTS 158 
In the pilot study (n=188), an association for a T>A mutation in rs7298346 and, to a lesser extent, for 159 
a C>T mutation in rs7308855 with the presence of renal failure at time of hospital admission was 160 
found in patients with ACLF (n=64, p=0.025 and p=0.103, respectively). The same mutations showed 161 
significant associations with lower 90-day survival in all patients (HR=1.81, 95%CI=1.02-3.23, p=0.044 162 
and HR=2.17, 95%CI=1.17-4.01, p=0.013, respectively). No association was found between SNPs and 163 
the presence of circulatory failure.  164 
Patient characteristics of the whole cohort study at time of hospital admission for AD of 165 
cirrhosis (n=641) or ACLF (n=185) are shown in table 1. All SNPs were in Hardy-Weinberg 166 
Equilibrium, except for rs10747983 (P<0.05). In contrast to the results of the pilot study, no 167 
association between the studied SNPs and the presence of renal failure or 90-day survival was 168 
found. Moreover, no association between SNPs and the presence of ACLF (table 1) or single 169 
circulatory, liver, cerebral or respiratory failure was found. When comparing patients with CLIF-170 
Organ Failure subscore 1 (normal or moderate organ dysfunction) vs. 2 (marked organ dysfunction) 171 
or 3 (organ failure), no associations between SNPs and these organ functions were found either. 172 
  Instead, a C>T mutation in SNP rs7308855 showed a significant association with the 173 
presence of ‘coagulation failure’ (defined as INR ≥2.5 according to CLIF-Organ Failure score) in 174 
cirrhotic patients admitted with AD or ACLF (table 2) and showed a clear trend towards the presence 175 
of coagulation failure in the subgroup of patients with ACLF (n=44, p=0.081). A trend was also found 176 
for a T>A mutation in SNP rs7298346 to be associated with the presence of coagulation failure in the 177 
whole study population (table 2) and in the subgroup of patients with ACLF (p=0.056). When 178 
comparing patients with CLIF-Organ Failure subscore 1 (n=643) vs. 2 and 3 (n=170), the same 179 
mutations in these SNPs were more frequently present in patients with subscore 2 or 3 as compared 180 
to patients with subscore 1 (p=0.050 and p=0.055, respectively). Despite of the association found for 181 
a mutation in SNP rs7308855 and rs7298346 with coagulation failure, median values of markers of 182 
coagulation function (INR, prothrombin time, activated partial thromboplastin time and platelet 183 
count) did not significantly differ between patients with or without a mutation in these SNPs.  184 
Finally, no association between the studied SNPs and survival after 28 days and 3, 6 and 12 185 
months of follow-up was found. 186 
 187 
DISCUSSION 188 
The results of the present study suggest that there is a weak association between two of the studied 189 
SNPs of AVP1aR with an INR ≥2.5 in patients admitted for AD of cirrhosis or ACLF. No associations 190 
with SNPs were found with the presence of other types of organ failure.  191 
 AVP1aR is widely expressed and is involved in diverse functions including vascular smooth 192 
muscle contraction [10]. The presence of peripheral vasodilation contributes to the development of 193 
portal hypertension in cirrhosis. The subsequent activation of endogenous vasoconstrictor systems, 194 
such as AVP, plays a role in the development of ascites, hyponatremia and hepatorenal syndrome 195 
[1,3]. In ACLF, activation of these vasoconstrictor systems is thought to contribute to the 196 
pathogenesis [2]. Because of its prominent role in the cardiovascular system, we hypothesized that 197 
genetic heterogeneity in AVP1aR might be involved in the development of organ failure in cirrhosis, 198 
especially in circulatory and renal failure. The present study is the first to investigate the implication 199 
of AVP1aR SNPs in recognizing cirrhotic patients with AD who are at risk of developing (multi-)organ 200 
failure.  201 
   We did not find an association with AVP1aR SNPs and the presence of ACLF, the majority of 202 
individual organ failures (i.e., renal, liver, circulatory, respiratory and cerebral failure) and outcome 203 
in the whole study cohort. Instead, an association was found between mutations in rs7308855 and 204 
rs7298346 and the presence of coagulation failure, which was defined as an INR≥2.5. Our 205 
observation of discrepancy between the results of the hypothesis-driven pilot study and the full 206 
cohort study once more underlines that results obtained in such a relatively small sample size pilot 207 
study, using stratified groups of patients, does not allow to draw firm conclusions, in our case on 208 
possible associations and trends between SNPs in AVP1aR and the development of renal failure and 209 
90-day survival.  210 
AVP1aR is expressed on the platelet membrane and is involved in the coagulation cascade 211 
[11]. Stimulation of AVP1aR activates the phosphatidyl-inositol-cascade leading to an increase in 212 
cytoplasmatic calcium and stimulation of platelet formation and aggregation [12, 13]. It has 213 
previously been shown that there is significant heterogeneity in the aggregation response of normal 214 
human platelets to AVP. The authors of that study hypothesized that this variability in aggregation 215 
response might be related to a SNP in AVP1aR [14]. A more recent study investigated the association 216 
between four SNPs in the promotor region of AVP1aR and platelet vasopressin responsiveness [15]. 217 
No significant associations were found in that study. There are no data available regarding the effect 218 
of heterogeneity of the thrombocyte aggregation response in cirrhosis. Coagulopathy is a major 219 
concern in chronic liver failure. Cirrhotic patients are at an increased risk of bleeding, due to portal 220 
hypertension and synthetic dysfunction of the liver. Increased bleeding tendency in cirrhosis is 221 
associated with an increased risk of morbidity and mortality in patients undergoing invasive 222 
procedures. In cirrhotic patients with sepsis, a common feature in ACLF, haemostasis seems to be 223 
even further impaired [16]. Therefore, identifying cirrhotic patients who are at an increased risk of 224 
bleeding might be beneficial for developing treatment and prevention strategies for these patients. 225 
However, further research in even larger cohorts of cirrhotic patients is needed in order to validate 226 
the results and to explore the pathophysiological mechanisms. The fact that markers of coagulation 227 
function were not different in patients with or without a mutation in rs7308855 and rs7298346, 228 
suggests that associations with coagulation failure found in the current study are rather indirect and 229 
not functionally reflected.  230 
  It is also important to consider that the definition of coagulation failure used in this study 231 
(INR≥2.5) does only represent the extrinsic pathway of the coagulation cascade. Furthermore, 232 
changes in INR are multifactorial. A more specific definition considering the function of the complete 233 
coagulation system should be applied in future studies.  234 
 We conclude that 6 SNPs of AVP1aR may not be useful as genetic markers to identify 235 
cirrhotic patients with AD who are at an increased risk of developing ACLF. However, an association 236 
of two genotypes (rs7308855 and rs7298346) with coagulation failure in patients with AD of cirrhosis 237 
or ACLF was found, which needs further functional evaluation.  238 
 239 
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 302 
Table 1. Baseline characteristics and distributions of 6 variants of vasopressin 1a receptor genotypes 303 
and allele frequencies in the study population 304 
Variable All patients 
(n=826) 
No ACLF 
(n=641) 
ACLF 
(n=185) 
p-value 
Age (y) 57.6±11.8 57.7±12.1 57.4±11.0 0.752 
Male gender, n (%) 525 (63.6) 405 (63.2) 120 (64.9) 0.675 
Etiology of cirrhosis, n (%)     
Alcohol 490 (60.0) 363 (57.3) 127 (69.4) 0.003 
HBV 39 (5.0) 33 (5.5) 6 (3.4) 0.266 
HCV 253 (32.4) 203 (33.7) 50 (28.3) 0.176 
NAFLD 39 (5.0) 28 (4.7) 11 (6.3) 0.389 
PBC 22 (2.8) 18 (3.0) 4 (2.3) 0.628 
Cryptogenic 50 (6.4) 42 (7.0) 8 (4.6) 0.247 
Other 52 (6.7) 44 (7.3) 8 (4.6) 0.202 
Organ failures  at baseline, n (%)     
Liver 116 (14.0) 42 (6.6) 74 (40.0) <0.001 
Kidney 109 (13.2) - 109 (58.9) - 
Cerebral 49 (5.9) 15 (2.3) 34 (18.4) <0.001 
Coagulation 61 (7.4) 17 (2.7) 44 (23.8) <0.001 
Respiration 18 (2.2) 4 (0.6) 14 (7.6) <0.001 
Circulation 34 (4.1) 4 (0.6) 30 (16.2) <0.001 
Laboratory data     
INR 1.5 (1.3-1.8) 1.5 (1.3-1.7) 1.8 (1.4-2.4) <0.001 
PT (s) 19 (16-26) 18 (16-25) 23 (17-32) 0.016 
APTT (s) 1.5 (1.2-31) 1.4 (1.2-30) 1.9 (1.3-37) 0.002 
Platelet count (x10
9
/L) 86 (55-137) 89 (56-139) 75 (51-121) 0.019 
Bilirubin (mg/dL) 3.0 (1.6-6.9) 2.8 (1.5-5.5) 6.7 (2.0-16.7) <0.001 
Creatinine (mg/dL) 1.0 (0.7-1.4) 0.9 (0.7-1.2) 2.2 (1.0-3.1) <0.001 
Sodium (mmol/L) 135±6 135±6 134±7 0.009 
CRP (mg/L) 18 (7-40) 15 (6-35) 27 (12-53) <0.001 
WBC (x10
9
/L) 6.0 (4.1-9.2) 5.7 (4.0-8.3) 7.7 (5.3-12.3) <0.001 
Genetic variants of AVP1aR, n (%)     
Rs113481894 
CC 
CT/ TT 
 
697 (82.5) 
144 (17.5) 
 
528 (82.8) 
110 (17.2) 
 
151 (81.6) 
34 (18.4) 
 
0.720 
Rs7298346 
TT 
TA/ AA 
635 (77.0) 
175 (21.2) 
497 (77.7) 
143 (22.3) 
138 (74.6) 
47 (25.4) 
0.384 
Rs11174817 
AA 
AG/ GG 
223 (27.1) 
601 (72.9) 
167 (26.1) 
472 (73.9) 
56 (30.3) 
129 (69.7) 
0.265 
Rs1042615 
AA 
AG/ GG 
129 (15.6) 
696 (84.4) 
99 (15.5) 
541 (84.5) 
30 (16.2) 
155 (83.8) 
0.805 
Rs10747983 
GG 
GC/ CC 
136 (72.3) 
52 (27.7) 
69 (74.2) 
24 (25.8) 
67 (70.5) 
28 (29.5) 
0.574 
Rs7308855 
CC 
CT/ TT 
692 (84.0) 
132 (16.0) 
541 (84.7) 
98 (15.3) 
151 (81.6) 
34 (18.4) 
0.321 
 305 
Results are described as numbers (percentage), mean ± standard deviation or median (interquartile 306 
range) 307 
 308 
APTT, activated partial thromboplastin time; AVP1aR, vasopressin 1a receptor; CRP, C-reactive 309 
protein; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; NAFLD, 310 
non-alcoholic fatty liver disease; PBC, primary biliary cholangitis; PT, prothrombin time; WBC, white 311 
blood cell count 312 
 313 
 314 
Table 2. The association of a mutation in two single nucleotide polymorphisms in the vasopressin 1a 315 
receptor gene with the presence of coagulation failure (INR≥2.5) in cirrhotic patients admitted for 316 
acute decompensation and acute-on-chronic liver failure. 317 
Variants No coagulation 
failure (n= 765) 
Coagulation failure 
(n= 61) 
p-value 
rs7308855, n (%) 
CC 
CT/ TT 
 
647 (84.8) 
116 (15.2) 
 
45 (73.8) 
16 (26.2) 
0.024 
rs7298346, n (%) 
TT 
TA/ AA 
 
594 (77.8) 
170 (22.5) 
 
41 (67.2) 
20 (32.8) 
0.060 
 318 
 319 
 320 
